Background
Methods
Patients and microarray data
Data analysis
Results
Quality control analysis of gene expression microarrays
Differentially expressed genes and pathways between all NSCLC with and without any viral DNA
All primary NSCLCs: virus carcinogenesis and oncogenic gene sets enriched in virus-infected specimens
KEGG ID | Name | Count | Pop.Hits | Fold Enrichment | FDR | Genes | Total list | |
---|---|---|---|---|---|---|---|---|
Over-expressed genes in Virus-infected primary NSCLC tumors | hsa04110 | Cell cycle | 23 | 124 | 4.121 | 0.000 | E2F2, CDC6, FZR1, E2F4, RBL1, SKP2, PKMYT1, CHEK1, CDC20, PTTG1, MCM2, CDK4, CDC25B, MCM6, CCNE1, CDC45, CCNB2, CCND2, TFDP2, BUB1, BUB1B, CCNA2, STAG1 | 311 |
hsa03050 | Proteasome | 10 | 44 | 5.050 | 0.001 | PSMF1, PSMC4, PSMC3, PSMD11, PSME2, PSMB3, PSMB2, PSMD2, PSMD3, PSME3 | 311 | |
hsa04115 | p53 signaling pathway | 12 | 67 | 3.979 | 0.002 | CCNE1, CCNB2, CCND2, SERPINB5, RRM2, BAX, CHEK1, PMAIP1, PERP, CDK4, GTSE1, SESN3 | 311 | |
hsa05203 | Viral carcinogenesis | 22 | 205 | 2.384 | 0.004 | HRAS, RBL1, UBR4, SKP2, ACTN1, CHEK1, CDC20, PMAIP1, MAPKAPK2, CDK4, SRF, PKM, CDC42, CCNE1, MAPK1, GTF2A1, CCND2, BAX, RANBP1, CCNA2, CHD4, DLG1 | 311 | |
hsa04120 | Ubiquitin mediated proteolysis | 16 | 137 | 2.595 | 0.015 | FZR1, UBE2A, SOCS1, CBL, UBE4B, SKP2, UBE2J1, SAE1, CDC20, KEAP1, UBE2L3, BRCA1, FANCL, PIAS2, PIAS1, UBE2S | 311 | |
hsa03015 | mRNA surveillance pathway | 12 | 91 | 2.930 | 0.030 | NXT1, NCBP2, SYMPK, FIP1L1, ALYREF, HBS1L, SRRM1, MSI2, SMG1, ETF1, PPP2R2B, PPP2R3C | 311 | |
hsa05166 | HTLV-I infection | 23 | 256 | 1.996 | 0.031 | DVL3, E2F2, IL6, HRAS, TLN2, SLC25A5, ELK1, CHEK1, CDC20, PTTG1, CD40, MYBL2, CDK4, SRF, MSX2, POLE2, ELK4, CCND2, BAX, SLC2A1, BUB1B, RANBP1, DLG1 | 311 | |
hsa03040 | Spliceosome | 13 | 133 | 2.172 | 0.187 | NCBP2, DHX8, SNRPA1, TRA2B, LSM6, U2SURP, ALYREF, SF3B3, CTNNBL1, SRSF4, TCERG1, SNRNP40, SNRPF | 311 | |
Under-expressed genes in Virus-infected primary NSCLC tumors | hsa04024 | cAMP signaling pathway | 18 | 198 | 2.804 | 0.003 | ACOX1, ATP1B1, ROCK1, ROCK2, ADCY6, PDE4D, PDE4C, ATP1A2, PPP1CB, PLCE1, GRIA1, ABCC4, RAP1A, HHIP, HCN4, ADCY10, CACNA1D, HCAR1 | 224 |
hsa04270 | Vascular smooth muscle contraction | 13 | 119 | 3.370 | 0.005 | ROCK1, PLA2G10, ROCK2, PPP1R12B, ADCY6, NPR2, ARHGEF12, PPP1CB, GNAQ, PLA2G12A, PLA2G12B, CACNA1D, PPP1R14A | 224 | |
hsa01100 | Metabolic pathways | 59 | 1228 | 1.482 | 0.015 | ACOX2, ACOX1, CYP3A5, COX11, SGMS2, AMT, ALG2, ADH1A, PPOX, GPAT2, HIBADH, ASAH1, PDHB, ASAH2, ASPA, PIGM, NDUFS8, BPNT1, AGPAT2, NDUFS1, COX15, IDUA, NMNAT2, C1GALT1C1, HMGCLL1, SUCLG2, COX4I2, LPIN2, CDS1, TAT, ALDH3B1, ATP6V1C1, PLCE1, ALOX15B, MGAT5, AOC1, PRODH, ME3, LOC102724788, ALDOB, CTPS2, PLA2G12A, PLCH1, B3GNT6, PLA2G12B, BDH2, HSD17B7, ACSL5, PLA2G10, B3GALT2, KL, MAOA, NAT1, ACSM3, DBT, PON2, AHCYL2, ABO, PON3 | 224 | |
hsa04390 | Hippo signaling pathway | 12 | 151 | 2.452 | 0.114 | BMP4, PARD6B, BMP2, TP53BP2, WTIP, FZD5, PPP1CB, BMP5, LLGL2, BMPR1A, CTNNB1, PPP2R2A | 224 | |
hsa04972 | Pancreatic secretion | 9 | 93 | 2.985 | 0.121 | ATP1B1, SLC12A2, GNAQ, PLA2G10, PLA2G12A, PLA2G12B, ADCY6, RAP1A, ATP1A2 | 224 | |
hsa00564 | Glycerophospholipid metabolism | 9 | 95 | 2.922 | 0.135 | GPD1L, LPGAT1, PLA2G10, PLA2G12A, PLA2G12B, LPIN2, GPAT2, CDS1, AGPAT2 | 224 | |
hsa04961 | Endocrine and other factor-regulated calcium reabsorption | 6 | 45 | 4.113 | 0.168 | ATP1B1, GNAQ, KL, PTH1R, ADCY6, ATP1A2 | 224 | |
hsa04510 | Focal adhesion | 14 | 206 | 2.096 | 0.182 | COL4A4, COL4A3, ROCK1, PAK3, ROCK2, FLT4, PPP1R12B, ITGA8, ITGA1, ITGA10, RAP1A, ACTN2, PPP1CB, CTNNB1 | 224 | |
hsa04146 | Peroxisome | 8 | 83 | 2.973 | 0.199 | ACOX2, ACOX1, HMGCLL1, NUDT12, PEX1, ABCD3, PEX13, ACSL5 | 224 |
Primary squamous cell carcinoma: differentially expressed genes varied depending on infection viral types
NSCLC Subtype | Virus (the number of tumors infected) | Gene Symbol | Average Expression when in Virus-uninfected | Average Expression in Virus-Infected | Fold Change | Up/Down in Virus-infected tumors | FDR q-value | Gene Description |
---|---|---|---|---|---|---|---|---|
Squamous cell carcinoma (n = 10) | BLV (n = 8) | PSG4 | 58.325 | 6.142 | 0.105 | down | 0.033 | pregnancy specific beta-1-glycoprotein 4 |
CPB2 | 124.383 | 8.635 | 0.069 | down | 0.156 | carboxypeptidase B2 | ||
PlpPV.1 (n = 2) | GCM1 | 7.393 | 39.660 | 5.365 | up | 0.067 | glial cells missing homolog 1 | |
SMR3A | 9.305 | 86.279 | 9.273 | up | 0.099 | submaxillary gland androgen regulated protein 3A | ||
STLV.1 (n = 2) | MYEOV | 8.732 | 60.041 | 6.876 | up | 0.048 | myeloma overexpressed | |
SPRR3 | 3205.815 | 15.053 | 0.005 | down | 0.048 | small proline rich protein 3 | ||
FMN2 | 13.410 | 503.286 | 37.532 | up | 0.056 | formin 2 | ||
GATA4 | 8.371 | 44.251 | 5.287 | up | 0.074 | GATA binding protein 4 | ||
LOC105375229 | 8.548 | 87.248 | 10.207 | up | 0.120 | uncharacterized LOC105375229 | ||
SEMA5B | 70.639 | 302.948 | 4.289 | up | 0.120 | semaphorin 5B | ||
CNTNAP4 | 7.677 | 44.480 | 5.794 | up | 0.197 | contactin associated protein like 4 | ||
STLV.2 (n = 3) | CRISP2 | 7.371 | 91.073 | 12.355 | up | 0.015 | cysteine rich secretory protein 2 | |
Adenocarcinoma (n = 10) | Any (n = 8) | ACTC1 | 31.21 | 6.37 | 0.20 | down | 0.187 | actin, alpha, cardiac muscle 1 |
PCSK2 | 260.71 | 19.03 | 0.07 | down | 0.144 | proprotein convertase subtilisin/kexin type 2 | ||
HBV (n = 2) | CEACAM8 | 6.00 | 226.44 | 37.74 | up | 0.000 | carcinoembryonic antigen related cell adhesion molecule 8 | |
PRSS1 | 9.37 | 238.98 | 25.49 | up | 0.035 | protease, serine 1 | ||
CALB2 | 12.70 | 244.70 | 19.27 | up | 0.056 | calbindin 2 | ||
NUDT4 | 6.41 | 25.36 | 3.96 | up | 0.109 | nudix hydrolase 4 | ||
NAP1L6 | 5.57 | 19.92 | 3.57 | up | 0.071 | nucleosome assembly protein 1 like 6 | ||
CEP170B | 192.56 | 68.38 | 0.36 | down | 0.083 | centrosomal protein 170B | ||
MTND6P4 | 5241.96 | 1570.27 | 0.30 | down | 0.109 | mitochondrially encoded NADH:ubiquinone oxidoreductase core subunit 6 pseudogene 4 | ||
NUP62 | 1710.30 | 406.58 | 0.24 | down | 0.012 | nucleoporin 62 kDa | ||
Y73SV (n = 6) | MARCH3 | 14.08 | 36.38 | 2.58 | up | 0.151 | membrane associated ring-CH-type finger 3 | |
ANKRD29 | 32.33 | 9.34 | 0.29 | down | 0.151 | ankyrin repeat domain 29 | ||
NMNAT2 | 70.41 | 11.09 | 0.16 | down | 0.151 | nicotinamide nucleotide adenylyltransferase 2 | ||
QSER1 | 386.06 | 47.97 | 0.12 | down | 0.151 | glutamine and serine rich 1 |